Ruslan Horblyuk

Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin

Allison Keshishian, Shital Kamble, Xianying Pan et al. · Thrombosis and Haemostasis · 2016 · 261 citations · Full text

Medicine, Cardiology, Pharmacotherapy +16

Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice

Xiaoyan Li, Steve Deitelzweig, Allison Keshishian et al. · Thrombosis and Haemostasis · 2017 · 161 citations · Full text

Medicine, Cardiology, Pharmacology +15

Economic Measurement of Medical Errors Using a Hospital Claims Database

Guy David, Candace Gunnarsson, Heidi C. Waters et al. · Value in Health · 2013 · 78 citations

Pharmacy, Health Services Administration, Pharmacoeconomics +16

Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach

Xiaoyan Li, Allison Keshishian, Melissa Hamilton et al. · PLoS ONE · 2018 · 37 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Patient-reported treatment burden of chronic immune thrombocytopenia therapies

T. Michelle Brown, Ruslan Horblyuk, Kelly M. Grotzinger et al. · BMC Blood Disorders · 2012 · 35 citations · Full text

Life Sciences, Hematology, Immunology +12